Table 4.
Patient Characteristics
| Controls (N=1126) |
Cases (N=591) |
|
|---|---|---|
| NSABP Trial | ||
| P1 | 138 (12.3%) | 79 (13.4%) |
| P2 | 988 (87.7%) | 512 (86.6%) |
| Type of Breast Event | ||
| Invasive Breast Cancer | 0 (0%) | 452 (76.5%) |
| DCIS | 0 (0%) | 139 (23.5%) |
| Treatment | ||
| Tamoxifen | 595 (52.8%) | 318 (53.8%) |
| Raloxifene | 531 (47.2%) | 273 (46.2%) |
| Age (yrs) at entry | ||
| Mean (SD) | 59.9 (7.30) | 59.9 (7.28) |
| Median | 59.0 | 59.0 |
| < 55 | 276 (24.5%) | 146 (24.7%) |
| 55–59 | 327 (29%) | 170 (28.8%) |
| 60–64 | 252 (22.4%) | 136 (23%) |
| 65+ | 271 (24.1%) | 139 (23.5%) |
| 5-year predicted breast cancer risk | ||
| Mean (SD) | 4.8 (2.40) | 4.9 (2.50) |
| Median | 4.2 | 4.5 |
| <=2.00% | 63 (5.6%) | 33 (5.6%) |
| 2.01–3.00% | 236 (21%) | 121 (20.5%) |
| 3.01=5.00% | 349 (31%) | 183 (31%) |
| >5.00% | 478 (42.5%) | 254 (43%) |
| History of LCIS at entry | ||
| NO | 918 (81.5%) | 479 (81%) |
| YES | 208 (18.5%) | 112 (19%) |
| History of Atypical Hyperplasia at entry | ||
| NO | 863 (76.6%) | 435 (73.6%) |
| YES | 263 (23.4%) | 156 (26.4%) |
| Number of First-degree Relatives with Breast Cancer | ||
| 0 | 338 (30%) | 198 (33.5%) |
| 1 | 544 (48.3%) | 268 (45.3%) |
| 2+ | 244 (21.7%) | 125 (21.2%) |
| Time (months) on Tamoxifen or Raloxifene | ||
| Mean (SD) | 47.2 (18.78) | 29.5 (20.30) |
| Median | 60.0 | 27.5 |